Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisatracurium Infusion vs Bolus in Pediatric ARDS
NCT05153525Phase 4Unknown
- Sponsor
- Tanta University
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cisatracurium in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Tanta University. Primary endpoint: Duration on mechanical ventilation at 10 days. Status: unknown.
02
Drugs
cisatracurium
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05153525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153525.